Kamel Abou Hussein, Director of Breast Medical Oncology at MD Anderson Cancer Center at Cooper, shared on LinkedIn:
“The FDA has approved giredestrant (Wilserdly) in combination with everolimus (Afinitor) for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer following recurrence during or after adjuvant endocrine therapy, or progression on at least one endocrine-based regimen in the metastatic setting.
This approval, based on the Phase III evERA Breast Cancer trial, represents an important advancement in the management of endocrine-resistant breast cancer.
Two complementary therapeutic strategies
- Giredestrant: an oral selective estrogen receptor degrader (SERD) targeting ER signaling.
- Everolimus: an mTOR inhibitor targeting an important pathway implicated in endocrine resistance.
The evERA trial demonstrated a meaningful progression-free survival benefit, reinforcing the importance of targeting both estrogen receptor signaling and the PI3K/AKT/mTOR pathway in this setting.
Several important takeaways for clinical practice
- ESR1 mutation testing is increasingly central to therapeutic decision-making in ER-positive metastatic breast cancer.
- Endocrine resistance is biologically complex and often requires strategies that address multiple signaling pathways.
- The expanding role of oral SERDs and rational targeted combinations continues to reshape treatment sequencing following CDK4/6 inhibitor-based therapy.
As our understanding of tumor evolution and acquired endocrine resistance continues to advance, biomarker-driven treatment selection is becoming increasingly important in delivering individualized care.
Another meaningful step forward for patients living with ER-positive metastatic breast cancer.”
You can also read:
- FDA Approves Giredestrant Plus Everolimus: A New Treatment Option for ESR1-Mutated Advanced Breast Cancer

- evERA Breast Cancer: Giredestrant Plus Everolimus Extends PFS After CDK4/6 Inhibitor Resistance.